Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...